Tumor Ablation Market Size, Share & Trends Analysis Report By Technology (Microwave, HIFU), By Treatment (Laparoscopic Ablation, Percutaneous Ablation), By Application (Liver Cancer, Lung Cancer), And Segment Forecasts, 2024 - 2030

Tumor Ablation Market Size & Trends

The global tumor ablation market size was estimated at USD 1.67 billion in 2023 and is anticipated to expand at a compound annual growth rate (CAGR) of 13.5% from 2024 to 2030. The rising prevalence of cancer and high demand for safer therapeutic options are major factors contributing to the market growth. According to the WHO, it is projected that around 10-11 million cancer cases will be diagnosed each year globally till 2030. Lucrative growth potential in currently available therapeutic options, and high demand for minimally and non-invasive therapies are the factors expected to drive market growth. The growing preference among both surgeons and patients for minimally invasive surgical procedures, due to their advantages like faster recovery, enhanced patient comfort, and reduced procedure time, is anticipated to be a key driver for the increased demand for advanced tumor ablation techniques.

Advanced tumor ablation procedures are generally performed on an outpatient basis and do not require any hospital admission compared with conventional therapies, thereby reducing the total healthcare cost. Ablative surgeries are the preferred therapy for tumors of smaller sizes. Thus, its procedural volume is indirectly dependent on the yearly cancer screening rates. The number of newly diagnosed cancer cases has dropped significantly during the COVID-19 pandemic owing to fewer screening initiatives undertaken by concerned authorities.

Technological advancements to enhance accuracy, portability, and cost-effectiveness are the factors that force market players to constantly improve and launch advanced tumor ablation devices. Image-guided equipment, HIFU, and cryoablation are major examples of these technological advancements. The utilization of internally cooled radiofrequency probes in the cooled radiofrequency denervation technique to expand the lesion's size is an emerging method that is expected to have a substantial impact on market growth. This technique enables complete denervation of the sacroiliac joint, which helps in pain management.

Technology Insights

The radiofrequency tumor ablation segment held the largest share of 32.7% in 2023. The dominance can be attributed to its advantages, such as specificity and efficiency in solid tumor ablation procedures in the kidney and liver. In addition, radiofrequency ablation can be used to treat multiple tumors at the same time, thus improving procedural efficiency with the use of multiple electrodes placed at different sites. This is expected to boost the adoption rate of advanced tumor ablation techniques. The success rate of radiofrequency/microwave ablation technology in eliminating small liver tumors is estimated to be greater than 85%. According to the NCBI report, recurrence of tumors in patients opting for surgical resection ranges from 30% to 70%. On the other hand, tumor recurrence is very low (0.7-8%) in cases of radiofrequency ablation for similar tumors.

The advantages of radiofrequency techniques to successfully treat tumors at early stages are expected to drive segment growth. Microwave ablation technology is anticipated to witness the fastest CAGR from 2024 to 2030. The energy a of microwave (MW) ablation device propagates electromagnetic fields, unlike electric current in a radiofrequency ablation device. This improves the application of microwave ablation technology in tissue with low electrical conductance, such as bones and lungs. Major benefits of this technology include larger tumor ablation volume, consistency in high temperature, low ablation pain, and optimal heating of the cystic mass. These benefits are anticipated to support segment growth. Furthermore, minimum procedure time (5-10 minutes), improved efficacy with minimal complications, and reduced hospital stay are expected to drive the growth further.

Treatment Insights

The percutaneous ablation segment dominated the market by capturing a share of about 56.7% in 2023. These procedures offer faster recovery, minimal scarring, and increased safety. In addition, factors, such as quick surgery time, patient comfort, and cost-efficiency, are anticipated to further boost the segment demand. However, higher complications associated with the system are anticipated to limit its growth, especially in hospitals lacking skilled professionals.

According to the NCBI report, percutaneous ablations are not feasible in about 25-55% of patients due to unfavorable tumor locations. The tumor recurrence rate is higher in percutaneous ablation, due to insufficient ablation of the tumors located deep inside the tissue. Additionally, percutaneous ablation is contraindicated in treating lesions that are very adjacent to the gastrointestinal tract, gall bladder, bile duct, and heart due to the high risk of tumor recurrence. Therefore, in such cases, laparoscopic ablation is efficient in providing long-term outcomes while simultaneously retaining minimal invasiveness. This is expected to boost the laparoscopic ablation segment growth during the forecast period.

Application Insights

Other segments dominated the market in 2023 by capturing a revenue share of about 28.8%. This segment includes various types of cancer, such as bone metastasis and ENT cancer. The availability of advanced methods and increasing cancer prevalence are anticipated to facilitate segment growth. The lung cancer segment is projected to expand at the fastest CAGR through 2030, aided by the rising number of lung cancer cases globally due to the growing prevalence of smoking. For instance, as per the WHO, tobacco smoking is the main factor behind lung cancer, accounting for approximately 85% of all reported cases.

The kidney cancer segment is anticipated to grow at a rapid pace from 2024 to 2030. Radiofrequency and microwave ablation technology are effective in the treatment of renal tumors. Patients having solitary kidneys, tumor size (less than 4cm), and a slow post-surgical recovery rate are prospects for ablation of kidney tumors. According to the American Cancer Society’s estimates for 2022, 79,000 new cases of renal cancer will be diagnosed. In addition, with the rising use of medical imaging, the number of diagnosed cases is expected to increase, thereby driving the demand for treatment procedures.

Regional Insights

North America dominated the market with a revenue share of 34.42% in 2023. Major factors contributing to the region’s growth include government support for quality healthcare, high purchasing power parity, availability of reimbursements, and increasing prevalence of cancer. For instance, in the U.S., the Patient Protection and Affordable Care Act (PPACA), promotes the quality and affordability of healthcare through health coverage policies, that reduce the cost of healthcare for an individual and the government. In addition, the precision medicine initiative in formulating tailored strategies on unique characteristics of diseases. Hence, such government initiatives are anticipated to improve the overall healthcare system, thus boosting market growth. Europe held a significant share in 2023. A greater extent of public funding in Europe’s healthcare system has contributed to its growth.

Moreover, the growing geriatric population coupled with government support to control cancer is estimated to boost this growth further. For instance, the European Cancer Observatory aims to create awareness about cancer, early diagnostic techniques, and advanced, minimally invasive therapeutic options. Asia Pacific is expected to register the fastest CAGR from 2024 to 2030. A rise in patient numbers and a strong presence of prominent healthcare providers in developing economies like India and China create avenues for market expansion. Moreover, this region is witnessing improvements in healthcare utilization with government support. For example, the Indian government extends financial aid to indigent cancer patients through the Health Minister Cancer Patient Fund (HMCPF) scheme. This is expected to stimulate demand for tumor ablation devices, fostering the region's growth.

Key Companies & Market Share Insights

Key players are improving their offerings by upgrading their products, leveraging important cooperative drives, and considering acquisitions and government approvals to increase their client base and gain a larger industry share. For instance, in April 2023, Johnson & Johnson Service Inc. announced that the first patient was treated in North America in its clinical Investigational Device Exemption (IDE) trial to evaluate the safety and efficacy of transbronchial microwave ablation using the NEUWAVE FLEX microwave ablation system. The MONARCH platform guided this system. 

Tumor Ablation Market Report Scope

Global Tumor Ablation Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the tumor ablation market report based on technology, treatment, application, and region:

• Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • Radiofrequency Ablation

  • Microwave Ablation

  • Cryoablation

  • Irreversible Electroporation Ablation

  • HIFU

  • Other ablation technologies

• Treatment Outlook (Revenue, USD Million, 2018 - 2030)

  • Surgical Ablation

  • Laparoscopic Ablation

  • Percutaneous Ablation

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Kidney Cancer

  • Liver cancer

  • Breast cancer

  • Lung cancer

  • Prostate cancer

  • Other cancer

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait